BR112017003710A2 - mono-, di- ou polissacarídeo usado como inibidor de metal na preparação de agente de direcionamento com grupamento funcional de 68ga-quelato - Google Patents

mono-, di- ou polissacarídeo usado como inibidor de metal na preparação de agente de direcionamento com grupamento funcional de 68ga-quelato

Info

Publication number
BR112017003710A2
BR112017003710A2 BR112017003710A BR112017003710A BR112017003710A2 BR 112017003710 A2 BR112017003710 A2 BR 112017003710A2 BR 112017003710 A BR112017003710 A BR 112017003710A BR 112017003710 A BR112017003710 A BR 112017003710A BR 112017003710 A2 BR112017003710 A2 BR 112017003710A2
Authority
BR
Brazil
Prior art keywords
mono
preparation
targeting agent
metal inhibitor
polysaccharide used
Prior art date
Application number
BR112017003710A
Other languages
English (en)
Other versions
BR112017003710B1 (pt
Inventor
LUXEN André
KAISIN Geoffroy
Wouters Ludovic
LÉONARD Marc
Voccia Samuel
Original Assignee
Anmi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anmi S A filed Critical Anmi S A
Priority to BR122021017474-1A priority Critical patent/BR122021017474B1/pt
Publication of BR112017003710A2 publication Critical patent/BR112017003710A2/pt
Publication of BR112017003710B1 publication Critical patent/BR112017003710B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

a presente invenção refere-se à utilização de inibidor de metal em reações de radiomarcação usando metais radioativos.
BR112017003710-6A 2014-08-29 2015-07-28 Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação BR112017003710B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021017474-1A BR122021017474B1 (pt) 2014-08-29 2015-07-28 Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE2014/0653 2014-08-29
BE2014/0653A BE1021191B1 (fr) 2014-08-29 2014-08-29 Kit pour radiomarquage.
PCT/EP2015/067213 WO2016030104A1 (en) 2014-08-29 2015-07-28 Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent

Publications (2)

Publication Number Publication Date
BR112017003710A2 true BR112017003710A2 (pt) 2017-12-05
BR112017003710B1 BR112017003710B1 (pt) 2021-12-14

Family

ID=52396314

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122021017474-1A BR122021017474B1 (pt) 2014-08-29 2015-07-28 Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação
BR112017003710-6A BR112017003710B1 (pt) 2014-08-29 2015-07-28 Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação
BR112017003578-2A BR112017003578B1 (pt) 2014-08-29 2015-07-28 Kit para radiomarcação compreendendo gálio-68 e um inibidor de metal, seu uso e seus processos de preparação, e método e processo para radiomarcação de um agente alvo com gálio-68

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122021017474-1A BR122021017474B1 (pt) 2014-08-29 2015-07-28 Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017003578-2A BR112017003578B1 (pt) 2014-08-29 2015-07-28 Kit para radiomarcação compreendendo gálio-68 e um inibidor de metal, seu uso e seus processos de preparação, e método e processo para radiomarcação de um agente alvo com gálio-68

Country Status (19)

Country Link
US (6) US11045563B2 (pt)
EP (4) EP3185911B1 (pt)
JP (2) JP6543343B2 (pt)
CN (2) CN106794265B (pt)
AU (7) AU2015309187B2 (pt)
BE (1) BE1021191B1 (pt)
BR (3) BR122021017474B1 (pt)
CA (3) CA2958475C (pt)
DK (1) DK3185911T3 (pt)
ES (2) ES2855991T3 (pt)
HU (1) HUE053971T2 (pt)
IL (2) IL250735B (pt)
MX (2) MX2017002362A (pt)
NZ (1) NZ729293A (pt)
PL (1) PL3185911T3 (pt)
PT (1) PT3185911T (pt)
RU (2) RU2725627C2 (pt)
WO (2) WO2016030103A1 (pt)
ZA (1) ZA201702152B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
BE1021191B1 (fr) * 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN106377527B (zh) * 2016-09-05 2019-02-26 郑州大学 开链吡啶羧酸衍生物H2dedpa在抗菌领域的应用
JP2020518673A (ja) 2017-05-05 2020-06-25 フュージョン・ファーマシューティカルズ・インコーポレイテッド 二官能性キレートの薬物動態増強及びその使用
IL313115A (en) 2017-05-05 2024-07-01 Centre For Probe Dev And Commercialization R1–IGF monoclonal antibodies and their use
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3720510A1 (en) * 2017-12-08 2020-10-14 Ecs-biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
WO2019246445A1 (en) * 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
CN110787186B (zh) * 2019-10-22 2020-11-17 华中科技大学 一种Ga3+/PDA靶向协同抗菌纳米材料、其制备和应用
IT202000032603A1 (it) 2020-12-29 2022-06-29 Univ Degli Studi Di Bari Aldo Moro Kit freddi a base di ligandi del psma per l’allestimento di radiofarmaci.
WO2022253785A2 (en) 2021-05-31 2022-12-08 Universität Heidelberg Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
KR20240051918A (ko) 2021-06-29 2024-04-22 라이프 몰레큘러 이미징 리미티드 방사성금속 표지된 킬레이트-관능화된 표적화 접합체의 방사성약제 제조를 위한 신규 키트

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7902342A (nl) 1979-03-26 1980-09-30 Byk Mallinckrodt Cil Bv Isotopengenerator.
US7230085B2 (en) 2001-11-28 2007-06-12 Immunomedics, Inc. Anti-DOTA antibody
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
ES2398393T3 (es) * 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
GB0308408D0 (en) 2003-04-11 2003-05-21 Amersham Plc Microwave activation
KR101106533B1 (ko) * 2003-07-24 2012-01-20 브라코 이미징 에스.피.에이. 안정한 방사성의약 조성물 및 제조 방법
US8147805B2 (en) 2005-01-05 2012-04-03 The Board of Regents of The University of T exas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
BRPI0809442A2 (pt) 2007-03-27 2014-09-09 Radiomedix Inc Composições para terapia e formação de imagens direcionada
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
US20120164111A1 (en) * 2009-04-14 2012-06-28 Kurt Osther Novel post-translational fibrinogen variants
WO2010141833A2 (en) 2009-06-05 2010-12-09 The General Hospital Corporation Vital fluorochrome conjugates and methods of use
US8951064B2 (en) 2010-12-14 2015-02-10 Ideal Industries, Inc. Terminal structures for wiring devices
ITFI20110180A1 (it) 2011-08-12 2013-02-13 Advanced Accelerator Applic S A Processo per la preparazione di complessi di 68ga.
US9161998B2 (en) * 2012-05-18 2015-10-20 Zentralklinik Bad Berka Gmbh Method and kit for preparing a radiopharmaceutical
US20150246146A1 (en) * 2012-10-25 2015-09-03 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
CN104830316B (zh) * 2015-05-11 2017-02-01 厦门大学 一种用于核素标记的靶向探针及其制备方法和应用
ITUA20163207A1 (it) 2016-05-06 2017-11-06 Azienda Ospedaliera Di Reggio Emilia Arcispedale Santa Maria Nuova Preparazione in kit di radiofarmaci marcati con gallio-68

Also Published As

Publication number Publication date
EP3185911A1 (en) 2017-07-05
EP3185912A1 (en) 2017-07-05
CN106794265B (zh) 2021-01-26
AU2022202346A1 (en) 2022-04-28
CN106659806A (zh) 2017-05-10
WO2016030103A1 (en) 2016-03-03
ES2855991T3 (es) 2021-09-27
US11040120B2 (en) 2021-06-22
WO2016030104A1 (en) 2016-03-03
AU2015309188A1 (en) 2017-03-09
CA2958471C (en) 2022-05-31
AU2022202439B2 (en) 2023-12-14
RU2017109582A (ru) 2018-10-01
IL250736A0 (en) 2017-04-30
EP3185911B1 (en) 2020-12-30
CA3167294A1 (en) 2016-03-03
AU2015309187A1 (en) 2017-03-09
US20180230069A1 (en) 2018-08-16
BR112017003578A2 (pt) 2017-12-05
CN106659806B (zh) 2021-01-26
PT3185911T (pt) 2021-03-22
DK3185911T3 (da) 2021-03-15
NZ729291A (en) 2021-03-26
MX2017002361A (es) 2017-09-15
RU2725627C2 (ru) 2020-07-03
EP3185912B1 (en) 2020-12-30
JP2017530188A (ja) 2017-10-12
BR112017003710B1 (pt) 2021-12-14
JP2017526745A (ja) 2017-09-14
US20180230068A1 (en) 2018-08-16
NZ729293A (en) 2022-04-29
CA3167294C (en) 2024-05-28
US20220273827A1 (en) 2022-09-01
AU2015309188B2 (en) 2020-05-21
AU2020220193A1 (en) 2020-09-10
RU2017109582A3 (pt) 2018-12-20
US20220296735A1 (en) 2022-09-22
AU2024205118A1 (en) 2024-08-15
IL250735B (en) 2021-04-29
MX2017002362A (es) 2017-09-15
US11045563B2 (en) 2021-06-29
AU2022202439A1 (en) 2022-05-05
ZA201702152B (en) 2021-06-30
CA2958471A1 (en) 2016-03-03
IL250735A0 (en) 2017-04-30
CA2958475C (en) 2022-07-12
JP6543343B2 (ja) 2019-07-10
BE1021191B1 (fr) 2015-10-27
EP3862026A1 (en) 2021-08-11
EP3862025A1 (en) 2021-08-11
HUE053971T2 (hu) 2021-07-28
CN106794265A (zh) 2017-05-31
US20210275697A1 (en) 2021-09-09
BR122021017474B1 (pt) 2023-10-10
RU2017109583A3 (pt) 2018-12-26
PL3185911T3 (pl) 2021-08-23
RU2724894C2 (ru) 2020-06-26
CA2958475A1 (en) 2016-03-03
JP6552622B2 (ja) 2019-07-31
BR112017003578B1 (pt) 2023-12-26
RU2017109583A (ru) 2018-10-01
IL250736B (en) 2021-04-29
US20210268131A1 (en) 2021-09-02
ES2856030T3 (es) 2021-09-27
AU2020220194A1 (en) 2020-09-10
AU2015309187B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
BR112017003710A2 (pt) mono-, di- ou polissacarídeo usado como inibidor de metal na preparação de agente de direcionamento com grupamento funcional de 68ga-quelato
GT201800090A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112017023853A2 (pt) composições de nanopartícula para terapia sustentada.
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
EP3649577C0 (en) APPLICATION FOR DETERMINING A READING/WORKING DISTANCE
FR3013218B1 (fr) Composition comprenant des capsules gelifiees stabilisees par un tampon
AR102677A1 (es) Composición que comprende sal de acil glutamato como agente tensoactivo primario o agente tensoactivo aniónico primario y polímeros estructurantes específicos
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
BR112017008481A2 (pt) composto antimicótico
BR122020011331B8 (pt) Artigo absorvente
ZA201704869B (en) Working neutron source
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
DK3296485T3 (da) Ståldrager
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
EP2980195A4 (en) HYDROSOLUBLE OILY AGENT FOR THE WORKING OF METALS
BR112018006446A2 (pt) composições lubrificantes e métodos para uso das mesmas
CL2016002677A1 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1.
BR112017011994A2 (pt) composições de sal metálico
BR112016026774A2 (pt) uso de inibidores de proteassoma contendo boro após terapia de câncer primária e composição farmacêutica.
PH12017500923A1 (en) New dosage and use of a a2a antagonist

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: TELIX INNOVATIONS S.A. (BE)

B25G Requested change of headquarter approved

Owner name: TELIX INNOVATIONS S.A. (BE)